Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Olivier Gaudreau

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 12, 2022
Optimal CCN4 Immunofluorescence for Tissue MicroarrayPierre-Olivier Gaudreau, Isabelle Cousineau, John Stagg
Journal of Clinical Psychopharmacology|September 16, 2006
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosisGabriella Gobbi, Pierre-Olivier Gaudreau, Nancy Leblanc
Oncoimmunology|July 29, 2016
CD73-adenosine reduces immune responses and survival in ovarian cancer patientsPierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, et al.
Immunity|June 21, 2018
Immune Checkpoint Blockade across the Cancer Care ContinuumBeth A Helmink, Pierre-Olivier Gaudreau, Jennifer A Wargo
Biomarkers in Cancer|May 12, 2016
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsPierre-Olivier Gaudreau, John Stagg, Denis Soulières, et al.
Clinical Lung Cancer|July 28, 2016
Immunotherapy Comes of Age in Lung CancerPriyanka Khanna, Normand Blais, Pierre-Olivier Gaudreau, et al.
Cancer Treatment and Research Communications|June 13, 2021
A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)Rami Nassabein, Pierre-Olivier Gaudreau, Wiam Belkaid, et al.
Immunotherapy|January 26, 2016
CD73-adenosine: a next-generation target in immuno-oncologyDavid Allard, Bertrand Allard, Pierre-Olivier Gaudreau, et al.
Clinical Lung Cancer|April 18, 2020
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial ReportPierre-Olivier Gaudreau, J Jack Lee, John V Heymach, et al.
American Journal of Hematology|September 30, 2009
Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and beta-thalassemia minorPierre-Olivier Gaudreau, Xiaoduan Weng, Ghislain Cournoyer, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|November 12, 2022
Optimal CCN4 Immunofluorescence for Tissue MicroarrayPierre-Olivier Gaudreau, Isabelle Cousineau, John Stagg
Journal of Clinical Psychopharmacology|September 16, 2006
Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosisGabriella Gobbi, Pierre-Olivier Gaudreau, Nancy Leblanc
Oncoimmunology|July 29, 2016
CD73-adenosine reduces immune responses and survival in ovarian cancer patientsPierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, et al.
Immunity|June 21, 2018
Immune Checkpoint Blockade across the Cancer Care ContinuumBeth A Helmink, Pierre-Olivier Gaudreau, Jennifer A Wargo
Biomarkers in Cancer|May 12, 2016
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsPierre-Olivier Gaudreau, John Stagg, Denis Soulières, et al.
Clinical Lung Cancer|July 28, 2016
Immunotherapy Comes of Age in Lung CancerPriyanka Khanna, Normand Blais, Pierre-Olivier Gaudreau, et al.
Cancer Treatment and Research Communications|June 13, 2021
A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)Rami Nassabein, Pierre-Olivier Gaudreau, Wiam Belkaid, et al.
Immunotherapy|January 26, 2016
CD73-adenosine: a next-generation target in immuno-oncologyDavid Allard, Bertrand Allard, Pierre-Olivier Gaudreau, et al.
Clinical Lung Cancer|April 18, 2020
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial ReportPierre-Olivier Gaudreau, J Jack Lee, John V Heymach, et al.
American Journal of Hematology|September 30, 2009
Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and beta-thalassemia minorPierre-Olivier Gaudreau, Xiaoduan Weng, Ghislain Cournoyer, et al.
Pageof 4